The Swiss drugmaker reported data for LCZ696 in August, which found
the drug cut the risk of both cardiovascular death and admissions to
hospital by a fifth.
Some analysts have suggested the medicine could notch up sales of
$8-$10 billion, but Novartis Chief Executive Joe Jimenez said he
thought those forecasts were a bit "too optimistic."
"Even though it's early, the data would support this drug being a
multi-blockbuster. I've seen estimates of somewhere between $2 and
$5 billion, and I think if you look at the data...I believe it
should fall in that ballpark," he told reporters on a third-quarter
results earning call.
"I think some of the analyst projections of between $8 and $10
billion are probably too optimistic, but again we don't know until
we launch the brand and see the reaction."
Jimenez said Novartis was on track to submit the drug to U.S. health
regulators by December and expects a decision by the Food and Drug
Administration towards the end of 2015.
(Reporting by Caroline Copley)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column]